D Tc 99m Dimercaptosuccinic Acid SPECT Versus Planar

Added Value of Tc99m Dimercaptosuccinic Acid SPECT Versus Planar Imaging in Detection of Renal Cortical Defects

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04091685

Enrollment

Registered

2019-09-17

Start date

2019-09-30

Completion date

2020-10-31

Last updated

2019-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dimercaptosuccinic Acid SPECT and Planar

Brief summary

Knowing what will DMSA spect add to the DMSA planar in detection in renal cortical defects

Interventions

DEVICEGamma camera imaging

Use gamma camera in detection of renal cortical defects

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Inclusion criteria

* patient with history of peylo nephritis.

Exclusion criteria

* pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Comparison between DMSA spect and planar imaging	Baseline	Analysis of DMSA spect and planar imaging to clarify early renal cortical defects

Secondary

Measure	Time frame	Description
Clarify added value of DMSA spect over planar	Baseline	Know if DMSA spect is necessary?

Contacts

Primary ContactMarwa Sayed Mahamed

marwasayed1599@gmail.com00201010573518

Backup ContactMohamed A Mekkawy, PhD

01223196777

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026